170 related articles for article (PubMed ID: 31910009)
1. Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer.
He J; Peng T; Peng Y; Ai L; Deng Z; Wang XQ; Tan W
J Am Chem Soc; 2020 Feb; 142(6):2699-2703. PubMed ID: 31910009
[TBL] [Abstract][Full Text] [Related]
2. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
[TBL] [Abstract][Full Text] [Related]
3. LLDT-288, a novel triptolide analogue exhibits potent antitumor activity in vitro and in vivo.
Xu H; Fan X; Zhang G; Liu X; Li Z; Li Y; Jiang B
Biomed Pharmacother; 2017 Sep; 93():1004-1009. PubMed ID: 28724258
[TBL] [Abstract][Full Text] [Related]
4. Triptolide and Its Derivatives as Cancer Therapies.
Noel P; Von Hoff DD; Saluja AK; Velagapudi M; Borazanci E; Han H
Trends Pharmacol Sci; 2019 May; 40(5):327-341. PubMed ID: 30975442
[TBL] [Abstract][Full Text] [Related]
5. Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin.
Zhang Z; Sun C; Zhang L; Chi X; Ji J; Gao X; Wang Y; Zhao Z; Liu L; Cao X; Yang Y; Mao W
Biomed Pharmacother; 2019 Jan; 109():1541-1546. PubMed ID: 30551406
[TBL] [Abstract][Full Text] [Related]
6. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
[TBL] [Abstract][Full Text] [Related]
7. Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation.
He QL; Minn I; Wang Q; Xu P; Head SA; Datan E; Yu B; Pomper MG; Liu JO
Angew Chem Int Ed Engl; 2016 Sep; 55(39):12035-9. PubMed ID: 27574181
[TBL] [Abstract][Full Text] [Related]
8. Engineering Exosomes Endowed with Targeted Delivery of Triptolide for Malignant Melanoma Therapy.
Jiang L; Gu Y; Du Y; Tang X; Wu X; Liu J
ACS Appl Mater Interfaces; 2021 Sep; 13(36):42411-42428. PubMed ID: 34464081
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Triptolide-Loaded Exosomes on the Proliferation and Apoptosis of Human Ovarian Cancer SKOV3 Cells.
Liu H; Shen M; Zhao D; Ru D; Duan Y; Ding C; Li H
Biomed Res Int; 2019; 2019():2595801. PubMed ID: 31240207
[TBL] [Abstract][Full Text] [Related]
10. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma.
Ling D; Xia H; Park W; Hackett MJ; Song C; Na K; Hui KM; Hyeon T
ACS Nano; 2014 Aug; 8(8):8027-39. PubMed ID: 25093274
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of triptolide-loaded micelles on tumorigenicity inhibition of human ovarian cancer.
Wang Y; Liu T; Li H
J Biomater Sci Polym Ed; 2016; 27(7):545-56. PubMed ID: 26786618
[TBL] [Abstract][Full Text] [Related]
12. Site-specific construction of triptolide-based antibody-drug conjugates.
Wei D; Mao Y; Xu Z; Chen J; Li J; Jiang B; Chen H
Bioorg Med Chem; 2021 Dec; 51():116497. PubMed ID: 34794002
[TBL] [Abstract][Full Text] [Related]
13. Triptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression.
Kong J; Wang L; Ren L; Yan Y; Cheng Y; Huang Z; Shen F
Toxicol Appl Pharmacol; 2018 Mar; 342():1-13. PubMed ID: 29407771
[TBL] [Abstract][Full Text] [Related]
14. Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo.
Liu Y; Xiao E; Yuan L; Li G
DNA Cell Biol; 2014 Jul; 33(7):418-25. PubMed ID: 24720675
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
[TBL] [Abstract][Full Text] [Related]
16. Enhanced anti-tumor activity of triptolide in combination with irradiation for the treatment of oral cancer.
Chen YW; Lin GJ; Hueng DY; Huang SH; Chia WT; Shieh YS; Ma KH; Sytwu HK
Planta Med; 2014 Mar; 80(4):255-61. PubMed ID: 24510366
[TBL] [Abstract][Full Text] [Related]
17. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
18. Broad targeting of triptolide to resistance and sensitization for cancer therapy.
Hou ZY; Tong XP; Peng YB; Zhang BK; Yan M
Biomed Pharmacother; 2018 Aug; 104():771-780. PubMed ID: 29807227
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
[TBL] [Abstract][Full Text] [Related]
20. Triptolide Suppresses Growth of Breast Cancer by Targeting HMGB1 in Vitro and in Vivo.
Jiang W; Chen M; Xiao C; Yang W; Qin Q; Tan Q; Liang Z; Liao X; Mao A; Wei C
Biol Pharm Bull; 2019 Jun; 42(6):892-899. PubMed ID: 30956264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
